Skip to Content
Merck

F9427

Fexofenadine hydrochloride

>98% (HPLC), H1 histamine receptor antagonist, powder

Synonym(s):

Fexofenidine hydrochloride, MDL 16455 hydrochloride, Terfenidine carboxylate hydrochloride

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C32H39NO4 · HCl
CAS Number:
153439-40-8
Molecular Weight:
538.12
UNSPSC Code:
12352200
PubChem Substance ID:
24278447
NACRES:
NA.77
MDL number:
MFCD00865710
Assay:
>98% (HPLC)
Form:
powder
Quality level:
100
Storage condition:
desiccated

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Fexofenadine hydrochloride, >98% (HPLC)

Quality Level

100

assay

>98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: soluble ≥5 mg/mL

originator

Sanofi Aventis

storage temp.

−20°C

SMILES string

Cl[H].CC(C)(C(O)=O)c1ccc(cc1)C(O)CCCN2CCC(CC2)C(O)(c3ccccc3)c4ccccc4

InChI

1S/C32H39NO4.ClH/c1-31(2,30(35)36)25-17-15-24(16-18-25)29(34)14-9-21-33-22-19-28(20-23-33)32(37,26-10-5-3-6-11-26)27-12-7-4-8-13-27;/h3-8,10-13,15-18,28-29,34,37H,9,14,19-23H2,1-2H3,(H,35,36);1H

InChI key

RRJFVPUCXDGFJB-UHFFFAOYSA-N

Gene Information

human ... HRH1(3269)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Application

Fexofenadine hydrochloride has been used as a non-cationic ampliphilic antihistamines in NCI-H661 cells and as a histamine H1 receptor antagonist in mice

Biochem/physiol Actions

Fexofenadine is used in treating allergic rhinitis and chronic idiopathic urticaria. It may give relief in bothersome symptom and is a second-generation antihistamines. Fexofenadine provides better relief compared to other antihistamines for nasal congestion. It is the active metabolite of terfenadine and bring down allergen-induced symptoms.
Fexofenadine is a non-sedating H1 histamine receptor antagonist.

Features and Benefits

This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000192110
0000147454
0000147454
0000192110
0000133027

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability
Lappin G, et al.
European Journal of Pharmaceutical Sciences, 40(2), 125-131 (2010)
Effect of the second-generation antihistamine, fexofenadine, on cough reflex sensitivity and pulmonary function
Dicpinigaitis PV and Gayle YE
British Journal of Clinical Pharmacology, 56(5), 501-504 (2003)
Jae-Bong Kim et al.
Journal of neuroinflammation, 21(1), 53-53 (2024-02-22)
Parkinson's disease (PD) is a common and costly progressive neurodegenerative disease of unclear etiology. A disease-modifying approach that can directly stop or slow its progression remains a major unmet need in the treatment of PD. A clinical pharmacology-based drug repositioning
Inhibitory effect of oblongifolin C on allergic inflammation through the suppression of mast cell activation
Lu Y, et al.
Molecular and Cellular Biochemistry, 406(1-2), 263-271 (2015)
Jürgen Brüning et al.
The Journal of pharmacy and pharmacology, 67(6), 773-781 (2015-02-14)
This study describes the general method for the determination of the crystal structures of active pharmaceutical ingredients (API) from powder diffraction data and demonstrates its use to determine the hitherto unknown crystal structure of fexofenadine hydrochloride, a third-generation antihistamine drug.
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service